CPI-CG-8

CPI-CG-8, also known as N-methyl-N-(2-indolylethyl)tryptamine, is a "relatively" selective serotonin 5-HT_2C receptor agonist of the tryptamine family.^[1][2]

Other namesN-Methyl-N-(2-indolylethyl)tryptamine

Drug classSerotonin 5-HT_2C receptor agonist

ATC code

• None

FormulaC₂₁H₂₃N₃

Quick facts Clinical data, Other names ...

CPI-CG-8

Clinical data
Other names	N-Methyl-N-(2-indolylethyl)tryptamine
Drug class	Serotonin 5-HT2C receptor agonist
ATC code	None
Chemical and physical data
Formula	C21H23N3
Molar mass	317.436 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN(CCC1=CNC2=CC=CC=C12)CCC3=CC(C=CC=C4)=C4N3
InChI InChI=1S/C21H23N3/c1-24(12-10-17-15-22-21-9-5-3-7-19(17)21)13-11-18-14-16-6-2-4-8-20(16)23-18/h2-9,14-15,22-23H,10-13H2,1H3 Key:PJYCXUOZLVUZNU-UHFFFAOYSA-N

Close

At the serotonin 5-HT_2C receptor, it showed 99.4% binding inhibition (a measure of affinity) at a concentration of 1,000 nM, had an activational potency (EC₅₀Tooltip half-maximal effective concentration) of 12.46 nM, and showed an activational efficacy (E_maxTooltip maximal efficacy) of approximately 80%.^[2] The pharmacokinetics of CPI-CG-8 in rodents have been studied.^[1]

The drug was developed by Collaborations Pharmaceuticals and was derived via modification of the psychedelic drug psilocin using generative machine learning through a platform called MegaSyn.^[1][2] CPI-CG-8 was first described in the scientific literature by 2024.^[2][1] It is of interest for the potential treatment of opioid use disorder and other conditions.^[1]